Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide reversibly inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By blocking this enzyme, the drug raises acetylcholine concentrations at nerve‑muscle junctions, enhancing cholinergic signaling and thereby strengthening muscle contractions and promoting gastrointestinal motility.

The dosage of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule to achieve the desired clinical effect while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. The drug should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Healthcare providers typically evaluate each case carefully before prescribing during these periods.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mestinon (pyridostigmine) is a reversible, peripherally acting anticholinesterase, similar to neostigmine but with a longer duration of action and fewer central nervous system effects. It is generally preferred for chronic management of myasthenia gravis, whereas other agents may be used for short‑term or specific clinical scenarios.

Mestinon should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mestinon is taken orally, usually in tablet form, with or without food as directed by the prescriber. The medication may be divided into multiple daily doses to maintain steady plasma levels and optimize symptom control.

The most serious risks include cholinergic crisis, which presents as severe muscle weakness, respiratory failure, and bradycardia, as well as bronchospasm and profound hypotension. Immediate medical attention is required if these symptoms occur.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any excipients, and in individuals with severe asthma or active bronchospasm where cholinergic stimulation could worsen airway obstruction. Caution is also advised for patients with significant cardiac conduction disorders.